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Our results showed that triple antiplatelet therapy was superior to dual antiplatelet therapy in decreasing thrombotic events, a finding possibly driven by a decrease in clopidogrel resistance. Risk factors for thrombotic events and in-stent restenosis in patients undergoing stent implantation are complex. 1 These include periprocedural and cardiovascular risk factors. So, there is no doubt that further large-scale prospective randomized clinical trials are needed to indicate the long-term outcomes of triple antiplatelet therapy.
